{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:56:13Z","timestamp":1781326573098,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA050769"],"award-info":[{"award-number":["K01DA050769"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drugalcdep.2025.112975","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:06:15Z","timestamp":1765803975000},"page":"112975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prescribing of controlled substances to adolescents and young adults enrolled in Medicaid, 2001\u20132019"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4056-8405","authenticated-orcid":false,"given":"Greta","family":"Bushnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-3406","authenticated-orcid":false,"given":"Stephanie","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gerhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3705","authenticated-orcid":false,"given":"Hillary","family":"Samples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112975_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5665\/sleep.3410","article-title":"National use of prescription medications for insomnia: NHANES 1999-2010","volume":"37","author":"Bertisch","year":"2014","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112975_bib2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-055226","article-title":"Benzodiazepine and stimulant prescriptions before overdose in youth","volume":"149","author":"Bushnell","year":"2022","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112975_bib3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamainternmed.2020.0989","article-title":"Trends in utilization of prescribed controlled substances in US commercially insured adults, 2004-2019","volume":"180","author":"Bykov","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112975_bib4","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/j.japh.2021.01.025","article-title":"Gabapentin controlled substance status","volume":"61","author":"Campbell","year":"2021","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib5","unstructured":"Centers for Disease Control and Prevention (CDC). 2025. Drug Overdose Surveillance and Epidemiology (DOSE) System: Nonfatal Overdose Emergency Department and Inpatient Hospitalization Discharge Data. Retrieved from \u3008https:\/\/www.cdc.gov\/drugoverdose\/nonfatal\/dose\/discharge\/dashboard\/index.html\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib6","unstructured":"Centers for Medicare & Medicaid Services. 2018. Medicaid.gov. Retrieved from \u3008https:\/\/www.medicaid.gov\/index.html\u3009"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112975_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1176\/appi.ajp.160.6.1041","article-title":"Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability","volume":"160","author":"Chambers","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2016.12.003","article-title":"Physician practices to prevent ADHD stimulant diversion and misuse","volume":"74","author":"Colaneri","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112975_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"13","key":"10.1016\/j.drugalcdep.2025.112975_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","article-title":"Trends in stimulant prescription fills among commercially insured children and adults - United States, 2016-2021","volume":"72","author":"Danielson","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112975_bib11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138945009788982513","article-title":"Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences","volume":"10","author":"Dauri","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib12","unstructured":"Drug Enforcement Administration. 2024. Table of Exempted Prescription Products: January 11, 2024. Retrieved from"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112975_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","article-title":"Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies","volume":"59","author":"Faraone","year":"2020","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112975_bib14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.5665\/sleep.3914","article-title":"Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999-2010","volume":"37","author":"Ford","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib15","series-title":"The effects of medicaid expansion under the ACA: Updated findings from a literature review","author":"Guth","year":"2020"},{"issue":"26","key":"10.1016\/j.drugalcdep.2025.112975_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital Signs: changes in opioid prescribing in the United States, 2006-2015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112975_bib17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-031526","article-title":"Rising stimulant overdoses among young people in the United States","volume":"147","author":"Hadland","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2025.0054","article-title":"Prescription stimulant use, misuse, and use disorder among US adults aged 18\u201364 years","author":"Han","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112975_bib19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","article-title":"Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale","volume":"27","author":"Hong","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112975_bib20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v67n0708","article-title":"Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Huang","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib21","unstructured":"IQVIA Government Solutions Inc. 2022. Stimulant Prescription Trends in the United States From 2012 - 2021. Retrieved from 3110 Fairview Park Drive Suite 400 Falls Church, VA 22042: \u3008https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/IQVIA_Report_on_Stimulant_Trends_from_2012-2021.pdf\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib22","article-title":"A hidden pandemic? Abuse of gabapentinoids: a brief review of recent studies","author":"Ispir","year":"2023","journal-title":"Curr. Drug Res Rev."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112975_bib23","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ajhp\/zxab486","article-title":"State-level response to gabapentin misuse in the United States: Implications and future direction","volume":"79","author":"Karavolis","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"17","key":"10.1016\/j.drugalcdep.2025.112975_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112975_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5335","article-title":"Overdiagnosis of attention-deficit\/hyperactivity disorder in children and adolescents: a systematic scoping review","volume":"4","author":"Kazda","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112975_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2025.112975_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0740-5472(91)90027-8","article-title":"History of benzodiazepine dependence","volume":"8","author":"Lader","year":"1991","journal-title":"J. Subst. Abus. Treat."},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112975_bib28","article-title":"Five-Year Trends in US Children's Health and Well-being, 2016-2020","volume":"176","author":"Lebrun-Harris","year":"2022","journal-title":"JAMA Pedia"},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112975_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36872","article-title":"Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017-2022","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad124","article-title":"Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008-2018: a sales data analysis","author":"Ma","year":"2023","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112975_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jama.2024.12030","article-title":"Adolescent use, diversion sources, and perceived procurement difficulty of prescription medications","volume":"332","author":"McCabe","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.addbeh.2016.08.021","article-title":"Medical and nonmedical use of prescription sedatives and anxiolytics: adolescents' use and substance use disorder symptoms in adulthood","volume":"65","author":"McCabe","year":"2017","journal-title":"Addict. Behav."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112975_bib33","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1360-0443.2007.02015.x","article-title":"Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study","volume":"102","author":"McCabe","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.addbeh.2018.11.010","article-title":"Age-specific risk of substance use disorders associated with controlled medication use and misuse subtypes in the United States","volume":"90","author":"McCabe","year":"2019","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112975_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ajad.12962","article-title":"Comparing changes in controlled substance prescribing trends by provider type","volume":"29","author":"Meadows","year":"2020","journal-title":"Am. J. Addict."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112975_bib36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in US adolescents: results from the national comorbidity study-adolescent supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112975_bib37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2105\/AJPH.2024.307745","article-title":"Trends in drug overdose deaths by intent and drug categories, United States, 1999-2022","volume":"114","author":"Nguyen","year":"2024","journal-title":"Am. J. Public Health"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112975_bib38","first-page":"27","article-title":"Dispensed opioid, buprenorphine, benzodiazepine, and stimulant prescriptions among Rhode Island Residents, 2017-2021","volume":"106","author":"Paiva","year":"2023","journal-title":"R. I Med J. (2013"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112975_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6409a1","article-title":"Controlled substance prescribing patterns--prescription behavior surveillance system, Eight States, 2013","volume":"64","author":"Paulozzi","year":"2015","journal-title":"MMWR Surveill. Summ."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112975_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamainternmed.2022.5268","article-title":"Trends in the concurrent prescription of opioids and gabapentin in the US, 2006\u20132018","volume":"183","author":"Peet","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112975_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s40429-018-0194-y","article-title":"Nonmedical prescription drug use among adolescents: global epidemiological evidence for prevention, assessment, diagnosis, and treatment","volume":"5","author":"Perlmutter","year":"2018","journal-title":"Curr. Addict. Rep."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112975_bib42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1037\/amp0000655","article-title":"Comorbid chronic pain and opioid misuse in youth: knowns, unknowns, and implications for behavioral treatment","volume":"75","author":"Pielech","year":"2020","journal-title":"Am. Psychol."},{"issue":"10222","key":"10.1016\/j.drugalcdep.2025.112975_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib44","unstructured":"Preuss, C.V., Kalava, A., & King, K.C. (2022). Prescription of Controlled Substances: Benefits and Risks. In StatPearls. Treasure Island (FL)."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112975_bib45","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamapediatrics.2021.1832","article-title":"Temporal trends in opioid prescribing practices in children, adolescents, and younger adults in the US From 2006 to 2018","volume":"175","author":"Renny","year":"2021","journal-title":"JAMA Pedia"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib46","unstructured":"Saunders H., R. R. 2022. Demographics and Health Insurance Coverage of Nonelderly Adults With Mental Illness and Substance Use Disorders in 2020. Medicaid. Retrieved from \u3008https:\/\/www.kff.org\/medicaid\/issue-brief\/demographics-and-health-insurance-coverage-of-nonelderly-adults-with-mental-illness-and-substance-use-disorders-in-2020\/#\u3009"},{"issue":"9826","key":"10.1016\/j.drugalcdep.2025.112975_bib47","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(12)60072-5","article-title":"Adolescence: a foundation for future health","volume":"379","author":"Sawyer","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112975_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/add.14440","article-title":"A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016","volume":"114","author":"Smith","year":"2019","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.drugalcdep.2025.112975_bib49","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00787-022-02066-8","article-title":"Killing pain?: a population-based registry study of the use of prescription analgesics, anxiolytics, and hypnotics among all children, adolescents and young adults in Norway from 2004 to 2019","volume":"32","author":"Stangeland","year":"2023","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112975_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.NT.0000269136.30749.5c","article-title":"FDA requests stronger label warnings on sleep drugs","volume":"7","author":"Stump","year":"2007","journal-title":"Neurol. Today"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib51","unstructured":"Substance Abuse and Mental Health Services Administration. 2022. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Retrieved from \u3008https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib52","unstructured":"Substance Abuse and Mental Health Services Administration. 2024. Drug Abuse Warning Network: National Estimates from Drug-Related Emergency Department Visits, 2023. Retrieved from Rockville, MD: \u3008https:\/\/www.samhsa.gov\/data\/\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib53","article-title":"Trends in Benzodiazepine Prescribing for US Adolescents and Young Adults From 2008 to 2019","author":"Toce","year":"2021","journal-title":"JAMA Pedia"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib54","unstructured":"U.S. Food and Drug Administration. 2016. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Retrieved from Silver Spring, MD: \u3008https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm518473.htm\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib55","unstructured":"U.S. Food and Drug Administration. 2019. FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. FDA Drug Safety Communication. Retrieved from \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia#:~:text=Health%20care%20professionals%20should%20not,to%20serious%20injuries%20or%20death\u3009."},{"key":"10.1016\/j.drugalcdep.2025.112975_bib56","unstructured":"U.S. Food and Drug Administration. 2020. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. FDA Drug Safety Communication. Retrieved from \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib57","unstructured":"U.S. Food and Drug Administration. 2023. FDA Drug Safety Communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. Retrieved from \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112975_bib58","unstructured":"United States Drug Enforcement Administration. 2024. DEA: Drug Information Retrieved from \u3008https:\/\/www.dea.gov\/drug-information\u3009"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112975_bib59","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112975_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.smrv.2017.06.009","article-title":"Insomnia disorder in adolescence: diagnosis, impact, and treatment","volume":"39","author":"de Zambotti","year":"2018","journal-title":"Sleep. Med Rev."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625004284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625004284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:09:57Z","timestamp":1781323797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625004284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"alternative-id":["S0376871625004284"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112975","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing of controlled substances to adolescents and young adults enrolled in Medicaid, 2001\u20132019","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112975"}}